DermaSensor

DermaSensor [Photo courtesy of DermaSensor]

Category: Health, Medical and Biotech
Subcategory: Noninvasive Medtech

From the winners: “The world’s first point-and-click skin cancer detection device for primary care providers. We equip America’s most common provider to detect the most common cancer. Our CE-marked, FDA breakthrough product is a handheld device that employs patented optical spectroscopy and machine learning technologies to effectively detect all common skin cancers.”

“It’s taken over nine years of product and clinical development efforts to bring DermaSensor to market abroad, and we hope to be approved soon by the FDA. The specific technology behind the device is called elastic scattering spectroscopy, or ESS, which we have protected with three issued patent families, two of which are licensed from our collaborator Boston University, as well as a machine learning database of thousands of biopsied, pathology-diagnosed lesions. Early studies were with Boston University’s microwave-sized, 30-pound, desktop spectroscopy systems. Over the last few years we’ve spent millions of dollars miniaturizing that 30-pound desktop system into a one-pound handheld device.”

“DermaSensor utilizes Elastic Scattering Spec. to take non-invasive samples of tissue, capturing cellular-level information from the skin lesion using dozens of wavelengths of light. The proprietary DermaSensor algorithm immediately assesses the data and provides a result in seconds, thereby better equipping the physician to detect skin cancer. There’s been significant uptake of using tape stripping of moles. However, this process takes the physicians several minutes for each lesion and takes a few days to get the lab results back.”

Previously: How DermaSensor aims to expand access to accurate skin cancer detection